Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.

Autor: Dilly J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Hoffman MT; Harvard Medical School, Boston, Massachusetts.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Abbassi L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Li Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Paradiso F; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Parent BD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Hennessey CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Jordan AC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Morgado M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Dasgupta S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Uribe GA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Yang A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Kapner KS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Hambitzer FP; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Qiang L; Harvard Medical School, Boston, Massachusetts.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Feng H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Geisberg J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wang J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Evans KE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Lyu H; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Schalck A; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Feng N; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lopez AM; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bristow CA; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kim MP; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rajapakshe KI; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bahrambeigi V; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Roth JA; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Garg K; Exact Sciences, Redwood City, California., Guerrero PA; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Stanger BZ; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Cristea S; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard School of Public Health, Boston, Massachusetts., Lowe SW; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Baslan T; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Mancias JD; Harvard Medical School, Boston, Massachusetts.; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Chan E; Amgen Inc., Thousand Oaks, California., Anderson A; Amgen Inc., Thousand Oaks, California., Katlinskaya YV; Amgen Inc., Thousand Oaks, California., Shalek AK; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.; Institute for Medical Engineering and Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts., Hong DS; University of Texas M.D. Anderson Cancer Center, Houston, Texas., Pant S; University of Texas M.D. Anderson Cancer Center, Houston, Texas., Hallin J; Mirati Therapeutics Inc., San Diego, California., Anderes K; Mirati Therapeutics Inc., San Diego, California., Olson P; Mirati Therapeutics Inc., San Diego, California., Heffernan TP; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chugh S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Christensen JG; Mirati Therapeutics Inc., San Diego, California., Maitra A; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Raghavan S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Nowak JA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Winter PS; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Dougan SK; Harvard Medical School, Boston, Massachusetts.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Publikováno v: Cancer discovery [Cancer Discov] 2024 Nov 01; Vol. 14 (11), pp. 2135-2161.